CRP	C-reactive protein
NSCLC	non-small cell lung cancer
ICI	immune checkpoint inhibitor(s)
PD-(L)1	programmed death (ligand) 1
PFS	progression-free survival
OS	overall survival
ORR	objective response rate
HR	hazard ratio
OR	odds ratio
CI	confidence interval
NGS	next-generation sequencing
(ir)RECIST	(immune-related) response evaluation criteria in solid tumors
PD	progressive disease
SD	stable disease
PR	partial remission
CR	complete remission
CTLA4	cytotoxic T-lymphocyte-associated protein 4
ECOG	Eastern cooperation oncology group performance status
BMI	body mass index
RTX	radiotherapy
CTX	chemotherapy
RCTX	radiochemotherapy
Q	quartile
Ref.	reference
EGFR	epidermal growth factor receptor
EML4–ALK	echinoderm microtubule associated protein-like 4 anaplastic lymphoma kinase
ROS1	ROS proto-oncogene 1
BRAF	v-Raf murine sarcoma viral oncogene homolog B